Of all helminths, schistosomes are considered as the "Masters of Regulation", while many studies conducted by the team of the project coordinator (Mr Capron) have identified a molecule certainly recognized as one of the best-researched enzyme molecules in schistosomes, now referred to as CA 995. Preliminary studies have showed that this molecule, combining immuno-regulatory properties and a detoxifying power on free radicals, may be one of the major factors involved in the reduction of intestinal inflammation. Moreover, this molecule has been successfully produced in a recombinant form and its safety and immunogenicity have been tested in 5 phases of clinical trials, including in children. This new therapeutic tool is potentially very interesting for controlling inflammatory diseases such as IBDs.

The aim of the project is to bring this molecule from a fundamental research stage to clinical studies on IBDs, and most particularly on pediatric Crohn's disease.

This work is made possible by the partnership of Biotechnology Company (IBD Biotech), specialized in the development of preclinical animal models for testing new molecules, two Inserm units with a broad range of complementary expertise, and a Clinical Investigation Center.

The expected results of this innovative project are highly important, as they will formally demonstrate the anti-inflammatory properties of CA 995 and its potential use in the prevention or the treatment of Crohn's disease. This would represent a major step in controlling this disease and these results may also be applied to other inflammatory conditions such as autoimmune diseases.

Support our research programs